10-Q Filing

MERCK & CO., INC. CIK: 310158 Q3 2020

Filing Information

Form Type	10-Q
Accession Number	`0000310158-20-000030`
Period End Date	20200930
Filing Date	20201105
Fiscal Year	2020
Fiscal Period	Q3
XBRL Instance	mrk-20200930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 56 Cash Flow Statement 70 Comprehensive Income 28

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$89.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$86.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$1.48B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.08B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.68B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.69B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.36B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.57B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$774.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)	`AccountsReceivableNetCurrent`	$8.42B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)	`AccountsReceivableNetCurrent`	$6.78B	USD	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6)	`InventoryNet`	$6.13B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6)	`InventoryNet`	$5.98B	USD	Point-in-time
Treasury Stock, Shares	`TreasuryStockShares`	1.04B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$4.28B	USD	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$4.67B	USD	Point-in-time
Treasury Stock, Shares	`TreasuryStockShares`	1.05B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$26.58B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$27.48B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.47B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.37B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019	`PropertyPlantAndEquipmentNet`	$15.05B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019	`PropertyPlantAndEquipmentNet`	$16.92B	USD	Point-in-time
Goodwill	`Goodwill`	$20.25B	USD	Point-in-time
Goodwill	`Goodwill`	$19.43B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$16.68B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$14.20B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$8.01B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$6.77B	USD	Point-in-time
Total Assets	`Assets`	$84.40B	USD	Point-in-time
Total Assets	`Assets`	$89.80B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.61B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.42B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.74B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.74B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$11.69B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$12.55B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$736.00M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$984.00M	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.57B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.59B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$20.41B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$22.22B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$26.32B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$22.74B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.78B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.47B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$11.97B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$12.03B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.66B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.49B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$51.11B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$46.60B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.38B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.19B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$81.86B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$86.00B	USD	Point-in-time
Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019	`TreasuryStockValue`	$55.95B	USD	Point-in-time
Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019	`TreasuryStockValue`	$56.81B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$29.19B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$25.91B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$84.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$94.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.00B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.88B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.27B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$89.80B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$84.40B	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$35.48B	USD	3 Qtrs
Sales	`Revenues`	$34.97B	USD	3 Qtrs
Sales	`Revenues`	$12.55B	USD	1 Quarter
Sales	`Revenues`	$12.40B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.99B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$9.95B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$10.44B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$3.48B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.59B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.38B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.73B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.45B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.72B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.20B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.32B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.39B	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$444.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$269.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$232.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$114.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$312.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$630.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-35.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-362.00M	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$9.12B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.05B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$24.70B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$26.30B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$8.67B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$2.35B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.43B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$10.78B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.61B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$483.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$440.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.26B	USD	3 Qtrs
Net Income	`ProfitLoss`	$2.94B	USD	1 Quarter
Net Income	`ProfitLoss`	$9.17B	USD	3 Qtrs
Net Income	`ProfitLoss`	$1.91B	USD	1 Quarter
Net Income	`ProfitLoss`	$7.41B	USD	3 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-73.00M	USD	3 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$12.00M	USD	3 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$6.00M	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.49B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.90B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$9.16B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.94B	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$3.62	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$2.91	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.16	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.74	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.74	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$2.89	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.16	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$3.61	USD	3 Qtrs

Cash Flow Statement 70 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$45.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$258.00M	USD	Point-in-time
Net income	`ProfitLoss`	$2.94B	USD	1 Quarter
Net income	`ProfitLoss`	$9.17B	USD	3 Qtrs
Net income	`ProfitLoss`	$1.91B	USD	1 Quarter
Net income	`ProfitLoss`	$7.41B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$2.72B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$2.72B	USD	3 Qtrs
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$35.00M	USD	3 Qtrs
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$864.00M	USD	3 Qtrs
Charge for acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	$982.00M	USD	3 Qtrs
Charge for acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	-	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-386.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$47.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$126.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$101.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$354.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$306.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$445.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$-219.00M	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.47B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$5.64B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$8.65B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$6.25B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$3.17B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.34B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$78.00M	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$2.38B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$7.46B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$1.89B	USD	3 Qtrs
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$2.54B	USD	3 Qtrs
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$3.62B	USD	3 Qtrs
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	$1.04B	USD	3 Qtrs
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	-	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$269.00M	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$907.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-141.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-320.00M	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.87B	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.67B	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-311.00M	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-3.89B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.95B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	-	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.96B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.42B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$1.28B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$3.73B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$4.29B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$4.67B	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$344.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$68.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-240.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-472.00M	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-6.85B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-4.20B	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$89.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-26.00M	USD	3 Qtrs
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-96.00M	USD	3 Qtrs
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.53B	USD	3 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.40B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.87B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.40B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.87B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.49B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.90B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$9.16B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.94B	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-153.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-9.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-137.00M	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$91.00M	USD	1 Quarter
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-18.00M	USD	3 Qtrs
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-17.00M	USD	1 Quarter
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$109.00M	USD	3 Qtrs
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-62.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-41.00M	USD	3 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-15.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-161.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$14.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-180.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$85.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-117.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-28.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$10.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-190.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$155.00M	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$7.64B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.87B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.95B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$8.97B	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.